Trial Profile
Therapeutic effects of direct renin inhibitor aliskiren added to AT1 receptor blocker in hypertensive patients with chronic kidney disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Benazepril (Primary)
- Indications Hypertension
- Focus Pharmacodynamics; Therapeutic Use
- 19 Sep 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
- 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 29 Apr 2012 Interim results presented at the 22nd European Meeting on Hypertension.